查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413066

多發性骨髓瘤藥物市場：按類型、配銷通路- 全球預測 2024-2030 年

Multiple Myeloma Therapeutics Market by Type (Chemotherapy, Radiation, Stem Cell Transplant & Supportive Treatment), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年多發性骨髓瘤治療市場規模為215.4億美元，2024年達229.5億美元，預計2030年將達347.4億美元，複合年成長率為7.06%。

多發性骨髓瘤藥物的全球市場

主要市場統計
基準年[2023] 215.4億美元
預測年份 [2024] 229.5億美元
預測年份 [2030] 347.4億美元
複合年成長率（%） 7.06%
多發性骨髓瘤治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估多發性骨髓瘤藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對多發性骨髓瘤治療市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-多發性骨髓瘤治療藥物市場的市場規模和預測是多少？

2-多發性骨髓瘤藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-多發性骨髓瘤藥物市場的技術趨勢和法律規範是什麼？

4-多發性骨髓瘤治療市場主要供應商的市場佔有率是多少？

5-進入多發性骨髓瘤藥物市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 血癌增加
      • 世界各地的老年人口正在增加
      • 對多發性骨髓瘤先進治療方法的需求不斷成長
    • 抑制因素
      • 多發性骨髓瘤治療費用高昂
    • 機會
      • 多種幹細胞移植手術的技術進步
      • 多發性骨髓瘤治療的持續研究和開發活動
    • 任務
      • 嚴格的政府規章制度
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章 多發性骨髓瘤藥物市場：依類型

  • 化療
    • 組乙醯酶(HDAC) 抑制劑
    • 免疫調節劑
    • 單株抗體
    • 蛋白酶體抑制劑
    • 常規化療
  • 輻射
  • 幹細胞移植和支持性治療

第7章 多發性骨髓瘤藥物市場：按配銷通路

  • 醫院藥房
  • 網路藥房
  • 零售藥局和藥局

第8章美洲多發性骨髓瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區多發性骨髓瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東及非洲多發性骨髓瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第12章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • Amgen, Inc.
    • Bristol-Myers Squibb Company
    • Celldex Therapeutics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genzyme Corporation
    • GlaxoSmithKline PLC
    • Innate Pharma SA
    • Johnson & Johnson Services, Inc.
    • Kesios Therapeutics Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-ED54C46E8368

[195 Pages Report] The Multiple Myeloma Therapeutics Market size was estimated at USD 21.54 billion in 2023 and expected to reach USD 22.95 billion in 2024, at a CAGR 7.06% to reach USD 34.74 billion by 2030.

Global Multiple Myeloma Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 21.54 billion
Estimated Year [2024] USD 22.95 billion
Forecast Year [2030] USD 34.74 billion
CAGR (%) 7.06%
Multiple Myeloma Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Multiple Myeloma Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multiple Myeloma Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Multiple Myeloma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen, Inc., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline PLC, Innate Pharma SA, Johnson & Johnson Services, Inc., Kesios Therapeutics Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Multiple Myeloma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Chemotherapy
      • Histone Deacetylase (HDAC) Inhibitors
      • Immunomodulating Agents
      • Monoclonal Antibodies
      • Proteasome Inhibitors
      • Traditional Chemotherapy
    • Radiation
    • Stem Cell Transplant & Supportive Treatment
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies & Drug Stores
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Multiple Myeloma Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multiple Myeloma Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Multiple Myeloma Therapeutics Market?

4. What is the market share of the leading vendors in the Multiple Myeloma Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Multiple Myeloma Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Multiple Myeloma Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the cases of blood cancers
      • 5.1.1.2. Increasing geriatric population across the globe
      • 5.1.1.3. Growing need for advanced therapeutics for multiple myeloma
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of multiple myeloma
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the multiple stem cell transplant procedures
      • 5.1.3.2. Ongoing research and development activities in multiple myeloma therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict rules and regulations of the government
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Multiple Myeloma Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
    • 6.3.1. Histone Deacetylase (HDAC) Inhibitors
    • 6.3.2. Immunomodulating Agents
    • 6.3.3. Monoclonal Antibodies
    • 6.3.4. Proteasome Inhibitors
    • 6.3.5. Traditional Chemotherapy
  • 6.3. Radiation
  • 6.4. Stem Cell Transplant & Supportive Treatment

7. Multiple Myeloma Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies & Drug Stores

8. Americas Multiple Myeloma Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Multiple Myeloma Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Amgen, Inc.
    • 12.1.3. Bristol-Myers Squibb Company
    • 12.1.4. Celldex Therapeutics, Inc.
    • 12.1.5. F. Hoffmann-La Roche Ltd.
    • 12.1.6. Genzyme Corporation
    • 12.1.7. GlaxoSmithKline PLC
    • 12.1.8. Innate Pharma SA
    • 12.1.9. Johnson & Johnson Services, Inc.
    • 12.1.10. Kesios Therapeutics Ltd.
    • 12.1.11. Merck & Co., Inc.
    • 12.1.12. Novartis AG
    • 12.1.13. Sanofi S.A.
    • 12.1.14. Takeda Pharmaceutical Company Limited
    • 12.1.15. Teva Pharmaceutical Industries Ltd.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MULTIPLE MYELOMA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE (HDAC) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TRADITIONAL CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RADIATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANT & SUPPORTIVE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 147. MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. MULTIPLE MYELOMA THERAPEUTICS MARKET LICENSE & PRICING